Announced details
Support for Kawasaki disease treatment selection; in vitro diagnostics
We have entered into a joint research agreement for the development of a product that simply detects Pentraxin 3 (PTX3) concentrations in blood qualitatively.
Shinjuku-ku, Tokyo; Representative Director and President, Wakunaga Hirohito (湧永 寛仁). Founded in 1955. Engages in the development, manufacture and sale of pharmaceuticals and health supplements, as well as the development of reagents and diagnostic products.
Pharmaceutical approval number: 30800EZX00039000. Registration date and expiry date: Not disclosed
The impact on our results for the current fiscal year is minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PTX3 Qualitative Kit to Support Kawasaki Disease Treatment Selection |
| Counterparty | Wakunaga Pharmaceutical Co., Ltd. |
| Counterparty overview | Shinjuku-ku, Tokyo; Representative Director and President, Wakunaga Hirohito (湧永 寛仁). Founded in 1955. Engages in the development, manufacture and sale of pharmaceuticals and health supplements, as well as the development of reagents and diagnostic products. |
| Relationship with the Company | We have entered into a joint research agreement for the development of a product that simply detects Pentraxin 3 (PTX3) concentrations in blood qualitatively. |
| Launch date | Preparing for launch (specific start date: Not disclosed) |
| Applicable area | Support for Kawasaki disease treatment selection; in vitro diagnostics |
| Registration number and expiry date | Pharmaceutical approval number: 30800EZX00039000. Registration date and expiry date: Not disclosed |
| Impact on Business Performance | The impact on our results for the current fiscal year is minor. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Wakunaga Pharmaceutical obtained manufacturing and marketing approval. Our company had entered into a joint research agreement with Wakunaga Pharmaceutical for the development of a product that simply detects PTX3 concentrations in blood qualitatively.